{
    "clinical_study": {
        "@rank": "149533", 
        "arm_group": [
            {
                "arm_group_label": "Furosemide PO - IV", 
                "arm_group_type": "Experimental", 
                "description": "Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)"
            }, 
            {
                "arm_group_label": "Furosemide IV - PO", 
                "arm_group_type": "Experimental", 
                "description": "IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n        -  To determine the absolute bioavailability of furosemide 500 mg (Lasix\u00ae Special) oral\n           formulation in patients with chronic renal failure undergoing peritoneal dialysis.\n\n      Secondary Objectives:\n\n        -  To determine the pharmacokinetic profiles of furosemide 500 mg (Lasix\u00ae Special) oral\n           formulation and 250 mg IV formulation\n\n        -  To compare the pharmacodynamic characteristics of furosemide 500 mg (Lasix\u00ae Special)\n           oral formulation and 250 mg IV formulation"
        }, 
        "brief_title": "Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Failure", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Screening: 7 to 10 days\n\n        -  Treatment period: 14 days (Period 1: 7 days; Period 2: 7 days)\n\n        -  End of study: 7 days after the last dosing,\n\n        -  Total duration from screening per subject: 22 to 25 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Male or female, 18 years old or older, with chronic renal failure undergoing\n             peritoneal dialysis for at least 3 months.\n\n          -  Women of childbearing age should have a negative pregnancy test before administration\n             of the study drug\n\n        Exclusion criteria:\n\n          -  Contra-indications to furosemide, including:\n\n               -  Hypersensitivity to furosemide or to sulphonamide-derived drugs or to any\n                  ingredient in the formulation or component of the container.\n\n               -  Glomerular filtration rate below 5 mL/min\n\n               -  Glomerular filtration rate above 20 mL/min\n\n               -  Severe liver disease\n\n               -  Patients with renal failure accompanied by hepatic coma and precoma\n\n               -  Renal failure due to poisoning with nephrotoxic or hepatotoxic substances\n\n               -  Severe hyponatremia, hypokalemia, hypovolemia, dehydration or hypotension\n\n               -  Nursing women\n\n          -  Pregnancy\n\n          -  Treatment with any diuretic, which cannot be discontinued with the required washout\n             period before the first drug administration\n\n          -  Existence of any surgical or medical condition, which, in the judgment of the\n             clinical investigator, might interfere with absorption, distribution, metabolism or\n             excretion of drugs.\n\n          -  Psychiatric or cognitive disturbance or illness, or recreational drug/alcohol use\n             that, in the opinion of the principal investigator, would affect patient safety\n             and/or compliance.\n\n          -  Treatment with the following inhibitors of secretion at the renal level:\n             clarithromycin, erythromycin, itraconazole, cyclosporin, ketoconazole, quinidine, and\n             verapamil, which cannot be discontinued during the course of the study.\n\n        Interfering substance:Subjects must abstain from alcohol and beverages containing\n        stimulating xanthine derivates (e.g. coffee and tea) during the entire study period.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724788", 
            "org_study_id": "FUROSL06121", 
            "secondary_id": "U1111-1127-0839"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Furosemide IV - PO", 
                    "Furosemide PO - IV"
                ], 
                "description": "Pharmaceutical form: Solution Route of administration: Intravenous", 
                "intervention_name": "FUROSEMIDE", 
                "intervention_type": "Drug", 
                "other_name": "Furosemide Special Injection"
            }, 
            {
                "arm_group_label": [
                    "Furosemide IV - PO", 
                    "Furosemide PO - IV"
                ], 
                "description": "Pharmaceutical form: Tablet Route of administration: Oral", 
                "intervention_name": "FUROSEMIDE (HOE058)", 
                "intervention_type": "Drug", 
                "other_name": "Lasix\u00ae Special"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Furosemide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "zip": "H1T 2M4"
                }, 
                "name": "Investigational Site Number 124002"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation (PRLasix\u00ae Special, Tablets 500 mg) in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Absolute bioavailability (F) of a single 500-mg oral tablet", 
            "safety_issue": "No", 
            "time_frame": "Day 1, 4, 8, 11"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To determine the pharmacokinetic parameters of furosemide (po and iv) measured by Cmax (maximum (peak) plasma drug concentration) after single dose administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 4, 8, 11"
            }, 
            {
                "measure": "To determine the pharmacokinetic parameters of furosemide (po and iv) measured by Tmax  (time to reach peak or maximum concentration) following drug administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 4, 8, 11"
            }, 
            {
                "measure": "To determine the pharmacokinetic parameters of furosemide (po and iv) measured by AUCT 0-72 (area under curve from the time zero to 72h)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 4, 8, 11"
            }, 
            {
                "measure": "To determine pharmacodynamic characteristics of furosemide (po and iv) including the excretion against time of urinary volume, urinary excretion, urea and creatinine", 
                "safety_issue": "No", 
                "time_frame": "0, 6, 12, 24 h"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}